Evolution of MET and NRAS gene amplification as acquired resistance mechanisms in EGFR mutant NSCLC

Tara L. Peters(University of Colorado Anschutz Medical Campus), Robert C. Doebele(University of Colorado Anschutz Medical Campus)

npj Precision Oncology

October 12, 2021

10.1038/s41698-021-00231-x

Cited by 11

Related Papers

An Activating KIT Mutation Induces Crizotinib Resistance in ROS1-Positive Lung Cancer

|Journal of Thoracic Oncology|2016|81

Novel Human-Derived RET Fusion NSCLC Cell Lines Have Heterogeneous Responses to RET Inhibitors and Differential Regulation of Downstream Signaling

|Molecular Pharmacology|2021|10

Intrinsic resistance to <scp>ROS1</scp> inhibition in a patient with <scp><i>CD74‐ROS1</i></scp> mediated by <scp>AXL</scp> overexpression

|Thoracic Cancer|2023|2